ICON shareholders vote in favour of all resolutions at its Annual General Meeting
23 Juillet 2013 - 12:30PM
Business Wire
ICON plc, (NASDAQ: ICLR), a global provider of
outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
all resolutions at the Annual General Meeting of the Company (AGM)
held on 22nd July 2013 (which resolutions had all been recommended
by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to
shareholders on 14th June 2013 and are available on
the ICON plc website.
The final results of voting on each of the items submitted to a
vote of shareholders during the AGM are as follows:
RESOLUTIONNUMBER
RESOLUTION TOTAL NUMBER OF VOTES
VOTE FOR VOTE AGAINST VOTE
WITHHELD 1.1 To re-elect Mr. Thomas
Lynch 51,674,203 51,474,431 133,020 66,752
1.2 To
re-elect Mr. Declan McKeon 51,674,203 51,506,997 100,445 66,761
1.3 To re-elect Prof. William Hall 51,674,203
51,517,884 89,558 66,761
2 To receive accounts and
reports 51,674,203 51,409,116 8,517 256,570
3 To
authorise the fixing of the auditors’ remuneration 51,674,203
47,640,947 3,965,491 67,765
4 To authorise the
Company to allot shares 51,674,203 44,580,855 7,013,214 80,134
5** To disapply pre-emption rights 51,674,203
45,337,820 6,251,874 84,509
6** To authorise the
Company to make market purchases of shares 51,674,203 51,122,122
13,329 538,752
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. In addition to the matters described in this press
release, the ability to maintain large client contracts or enter
into new contracts, maintain client relationships and the ability
to manage the opening of new offices, the integration of new
business mergers and acquisitions, as well as other risks and
uncertainties detailed from time to time in reports filed with the
US Securities and Exchange Commission by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements.
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 78
locations in 37 countries and has approximately 10,170 employees.
Further information is available at www.iconplc.com.
ICON/ICLR-F
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024